Dow Jones
38.441,54 -411,32 (-1,06%) Nasdaq
16.920,58 -99,30 (-0,58%) Nikkei 225
37.974,47 -582,40 (-1,51%) EUR/USD
1,0800 -0,0007 (-0,06%) Bitcoin EUR
62.917,33 -717,77 (-1,13%) CMC Crypto 200
1.459,05 -25,65 (-1,73%)
Incyte Corporation (4INCY.TI)
| Chiusura precedente | 52,82 |
| Aperto | 54,78 |
| Denaro | 52,06 x N/D |
| Domanda | 53,22 x N/D |
| Min-Max giorno | 54,36 - 54,78 |
| Intervallo di 52 settimane | 47,41 - 60,92 |
| Volume | |
| Media Volume | 12 |
| Capitalizzazione | N/D |
| Beta (mensile su 5 anni) | 0,69 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | 30 lug 2024 - 05 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireKnight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, the Brazilian health regulatory agency, under the rare diseases approval pathway, for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor recepto
